Evaluation of the Analgesic Effect of Direct Current Stimulation in the Treatment of Pelvic Pain,… (NCT07237165) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluation of the Analgesic Effect of Direct Current Stimulation in the Treatment of Pelvic Pain, Comparing Three Groups: Trans-spinal Stimulation, Ganglionic Stimulation, and Placebo. A Randomized Double-blind Study
France60 participantsStarted 2025-12-01
Plain-language summary
The purpose of this study is to evaluate the analgesic effectiveness of direct current stimulation (tsDCS) in the treatment of pelvic pain by comparing three groups:
* Trans-spinal tsDCS stimulation,
* Ganglionic tsDCS stimulation,
* Placebo (sham) tsDCS stimulation.
Who can participate
Age range
18 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient aged 18 to 85 years, suffering from pelvic pain for more than one year (excluding musculoskeletal causes).
* Patient with stable ongoing medication (analgesic or otherwise) for at least one month.
* Patient for whom lack of response to conventional treatments has led the pain specialist or referring physician to consider non-pharmacological therapeutic options.
* Patient reporting a pain intensity score \>3 on the Numeric Visual Pain Scale (NVPS) during pre-screening.
* Patient affiliated with the national health insurance system or an equivalent scheme.
* Patient who has provided written informed consent.
Exclusion Criteria:
* History of drug addiction.
* History of psychiatric disorders likely to interfere with the proper conduct of the study.
* Patient with skin lesions in the lumbar region.
* Person unable to understand the study protocol.
* Individuals covered by Articles L1121-5 to L1121-8 of the French Public Health Code, corresponding to all protected persons: pregnant women, women in labor, breastfeeding mothers, individuals deprived of liberty by judicial or administrative decision, or under legal protection.
* Subject currently in the exclusion period of another clinical trial
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Evolution of Pain
Timeframe: Pain progression will be assessed from week 1 (before treatment) to week 7 (end of treatment)